ClinicalTrials.gg
RecruitingNCT07240896Updated Jan 20, 2026

A Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101)

An Early Phase 1 interventional study of Group 1: DSL101 Low dose and Group 2: DSL101 Medium dose in Wilsons Disease, sponsored by DSciLab Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by DSciLab Co., Ltd. · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Hepatolenticular Degeneration with a site in China — 10 open to participants now, 11 under way, 1 of them phase 3. Hepatolenticular Degeneration · China.

Started
2025
the only one that year
Phase 1
3 of 15
2 open now
Primary completion
2028-04
later than 8 of 10 live
Registered
13th of 15
by date
Lead sponsor
1 of 15
DSciLab Co., Ltd.

Among the 15 studies in Hepatolenticular Degeneration with a site in China, this one is the only one that started in 2025, is one of 3 in phase 1, reaches primary completion later than 8 of the 10 other live ones, and was the 13th registered.

Hepatolenticular Degeneration

80 studies on the registry are indexed under Hepatolenticular Degeneration; 31 are open to participants now.

Browse Hepatolenticular Degeneration studies →

Open to participants now

10 of the 15 studies in Hepatolenticular Degeneration with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 22 Hepatolenticular Degeneration studies recruiting now, 17 (77%) set no upper age limit and 4 (18%) stop at 75 or younger; 14 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Hepatolenticular Degeneration with a site in China, or all of them as a file.
02

Study summary

This study adopted an open, single-arm, non-randomized, dose-escalation research design, aiming to evaluate the safety, tolerability, preliminary efficacy, pharmacokinetic and immunogenicity characteristics of single and multiple intravenous infusions of DSL101 in patients with Wilson's disease.

Read the detailed description

In this study, low, medium and high dose groups were preset, the low dose group was accelerated titration group, and the medium and high dose groups used the traditional "3+3" method combined with Sentinel method for dose escalation.

03

Conditions studied

  • Wilsons Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years old, gender not limited.
  2. Meet the diagnostic criteria f Wilson's Disease in "Guidelines for Diagnosis and Treatment of Wilson's Disease (2022 Edition)", with a Leipzig score ≥4, at least one year between diagnosis and screening; ceruloplasmin level \<0.1g/L.
  3. Patinets with Wilson's disease confirmed by laboratory tests to have double-chromosome mutations in the ATP7B gene.
  4. Low copper diet for at least six months befoer screening and willing to continue low copper diet during study.
  5. Fertile subjects agreed to adopt reliable contrraceptive methods from the screening until 6 months after the last administration.
  6. The subjects are atable patients with WD who have been trasted for at least six months without drug or dose changes for at least 6 momths at the time of screening , and have continuously used standard treatments [SOC, such as D-penicillamine, sodiu dihydroxypropane sulfonate, dimercaptosuccinic acid, trientine, and zinc preparations (zinc acetate, zinc gluconate, zinc sulfate)] for at least 6 months screening, and allowed subjects to continue with their prior SOC treatment.
  7. The subject's condition was fully controlled after treatment, and its definition must meet all of the following conditions:

    1. Serum NCC level ≥ 25 μg/L and ≤ 150 μg/L;
    2. Urinary copper ≥100 μg/24 hours and ≤900 μg/24 hours;;
    3. \< 2 times of value (ULN);
    4. The investigator believes that no other laboratory values or clinical symptoms would stop current standard therapy;
  8. Subjects with good compliance, who can understand and cooperate to complete the requirements of protocol.
  9. The subjects voluntarily participated in the trial and signed the form.

Exclusion criteria

Exclusion Criteria:

  1. Allergy or intolerance to the drug.
  2. Wilson's disease is accompanied by severe complications such as neurological and mental disorders.
  3. History of liver transplantation.
  4. Other liver-related diseases and clinical symptoms that can cause liver injury, such as acute and chronic hepatitis, alcoholic liver disease, liver disease, drug-induced liver injury, liver cirrhosis, liver ascites, esophageal varices, hepatic encephalopathy, hepatorenal syndrome, liver failure, liver , etc.; Subjects with Model for end-stage liver disease score (MELD)>13.
  5. Other diseases that can cause hemolysis or anemia, such as erythrocytosis, Mediterranean anemia, hemolytic anemia, various causes of infection, large area burns, etc.
  6. Other diseases that can cause dysfunction of the nervous system, such as Parkinson's disease, Parkinson syndrome, various causes of dystonia, chorea, primary tremor, epilepsy, mental abnormalities (such as history of schizophrenia or suicide attempts), etc.
  7. Screening period laboratory examination indicators:

    1. \< 90 g/L;
    2. ≤30 mL/min, or \<45 mL/min/1.73 m²;
    3. TBil≥2×,ALP/TBil\<4,/ALT>2.2;
    4. \< 70 ×10\^9/L;
    5. Neutrophils \< 1.0 × 10\^9 /L.
  8. History of gastrointestinal bleeding within six months before screening.
  9. Subjects with history of moderate to severe depression, suicidal thoughts or behaviors and serious psychiatric within 6 months prior to screening.
  10. Subjects who have uncontrolled diseases of thr heart, liver, kidneys, endocrine system, digestive tract, metabolism, blood, or malignant tumors.
  11. Active virus infection or active virus infection, or antibody positive.
  12. Pregnant women or lactating women.
  13. Subjects who have participated other clinical trial within 3 months prior to screening or plan to participate during the clinical trial.
  14. Investigators evaluate other subjects who are not suitable to participate in this clinical trial.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Group 1: DSL101

    Subjects will receive intravenous infusions of DSL101 once every four weeks.

    Drug: Group 1: DSL101 Low dose

  • Experimental
    Group 2: DSL101

    Subjects will receive intravenous infusions of DSL101 once every four weeks.

    Drug: Group 2: DSL101 Medium dose

  • Experimental
    Group 3: DSL101

    Subjects will receive intravenous infusions of DSL101 once every four weeks.

    Drug: Group 3: DSL101 High dose

Interventions

  • DrugGroup 1: DSL101 Low dose

    Subjects will receive intravenous infusions of DSL101 once every four weeks.

  • DrugGroup 2: DSL101 Medium dose

    Subjects will receive intravenous infusions of DSL101 once every four weeks.

  • DrugGroup 3: DSL101 High dose

    Subjects will receive intravenous infusions of DSL101 once every four weeks.

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events and serious adverse events

    Time frame: up to 56 weeks

Secondary outcomes

  1. Change in 24 hour urine copper

    Time frame: up to week 20

  2. Change in sum total cpper [ serum copper bound by ceruloplasmin (NCC) ]

    Time frame: up to week 20

  3. Change in serum free copper

    Time frame: up to week 20

  4. Change from baseline in serum ceruloplasmin

    Time frame: up to week20

  5. Change in serum iron concentration and serum ferritin concentration

    Time frame: up to week 20

  6. Clinical laboratory test: Biochemistry - alanine aminotransferase (ALT)

    The physician will judge whether an abnormality is clinically significant

    Time frame: up to week 20

  7. Change in the total score of the Unified Wilson Disease Rating Scale (UWDRS )

    The UWDRS scale consists of three parts: neurological, liver function and mental symptom. The higher scores mean a worse outcome.

    Time frame: up to week 20

  8. Number of subjects and percentage decrease in standard of care (SOC) medication euse within 20 weeks of administration

    Time frame: up to week 20

  9. PK: Average steady-state concentration (Cav,ss)

    Time frame: up to week 6

  10. Change from baseline in seurm ceruloplasmin activity

    Time frame: up to week20

  11. Clinical laboratory test: Biochemistry - aspartate aminotransferase (AST)

    Time frame: up to week 20

  12. Clinical laboratory test: Biochemistry - alkaline phosphatase (ALP)

    Time frame: up to week 20

  13. Clinical laboratory test: Biochemistry - gamma-glutamyltransferase (γ-GGT)

    Time frame: up to week 20

  14. Clinical laboratory test: Biochemistry - total bilirubin (TBIL)

    Time frame: up to week 20

Other outcomes

  1. PK: Cmax

    Time frame: up to week 6

  2. PK: Time to reach peak plasma concentration (Tmax)

    Time frame: up to week 6

  3. PK: Area under the plasma concentration-time curve (AUC)

    Time frame: up to week 6

  4. Immunogenicity: Positive rate of anti-drug antibody (ADA)

    Time frame: up to week 20

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — The study is in early stages and will consider releasing related information when sufficient data is available in subjects.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Apr 2028, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2025
First posted
Nov 21, 2025
StartActual
Dec 31, 2025
Primary completionEst.
Apr 2028
CompletionEst.
Apr 2029
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07240896
Lead sponsor
DSciLab Co., Ltd.
Responsible party
Sponsor
First posted
Nov 21, 2025
Start date
Dec 31, 2025
Primary completion
Apr 2028 (estimated)
Completion
Apr 2029 (estimated)
Last update
Jan 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion